Abstract：Atopic dermatitis is a chronic inflammatory skin disease related to impaired epidermal barrier function and immune function imbalance. Its pathogenesis is closely related to the Janus kinase (JAK)-signal transduction and activator of transcription (STAT) signaling pathway. According to blocking the JAK-STAT signaling pathway mediated by interleukin (IL)-4, IL-13, IL-31 and other related cytokines, it affects the expression of downstream genes, thereby treating atopic dermatitis. This article reviews recent studies on the involvement of JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis and the application of JAK inhibitors in atopic dermatitis.
杨立婷 吴黎明. Janus激酶抑制剂治疗特应性皮炎的研究进展[J]. 中国医药导报, 2021, 18(6): 59-62.
YANG Liting WU Liming. Research progress of Janus kinase inhibitors in the treatment of atopic dermatitis. 中国医药导报, 2021, 18(6): 59-62.
[1] Napolitano M，Megna M，Patruno C，et al. Adult atopic dermatitis：a review [J]. G Ital Dermatol Venereol，2016，151（4）：403-411.
[2] Simpson E，Udkoff J，Borok J，et al. Atopic dermatitis：emerging therapies [J]. Semin Cutan Med Surg，2017，36（3）：124-130.
[3] Villarino AV，Kanno Y，O’Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system [J]. Nat Immunol，2017，18（4）：374-384.
[4] Weidinger S，Beck LA，Bieber T，et al. Atopic dermatitis [J]. Nat Rev Dis Primers，2018，4（1）：1.
[5] Guttman-Yassky E，Silverberg JI，Nemoto O，et al. Baricitinib in adult patients with moderate-to-severe atopic dermatitis：a phase 2 parallel，double-blinded，randomized placebo-controlled multiple-dose study [J]. J Am Acad Dermatol，2019，80（4）：913-921.
[6] Wolk K，Witte E，Witte K，et al. Biology of interleukin-22 [J]. Semin Immunopathol，2010，32（1）：17-31.
[7] Seltmann J，Roesner LM，Wittmann M，et al. IL-33 impacts on the skin barrier by downregulating the expression of filaggrin [J]. J Allergy Clin Immunol，2015，135（6）：1659-1661.
[8] Sehra S，Yao Y，Howell MD，et al. IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation [J]. J Immunol，2010，184（6）：3186-3190.
[9] Ong PY，Ohtake T，Brandt C，et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis [J]. N Engl J Med，2002，347（15）：1151-1160.
[10] Totté JE，van der Feltz WT，Hennekam M，et al. Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis：a systematic review and meta-analysis [J]. Br J Dermatol，2016，175（4）：687-695.
[11] Schwartz DM，Kanno Y，Villarino A，et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases [J]. Nat Rev Drug Discov，2017，16（12）：843-862.
[12] Gandhi NA，Bennett BL，Graham NM，et al. Targeting key proximal drivers of type 2 inflammation in disease [J]. Nat Rev Drug Discov，2016，15（1）：35-50.
[13] Welsch K，Holstein J，Laurence A，et al. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors [J]. Eur J Immunol，2017，47（1）：1096-1107.
[14] Honda T，Miyachi Y，Kabashima K. Regulatory T cells in cutaneous immune responses [J]. J Dermatol Sci，2011， 63（2）：75-82.
[15] Zhang Y，Zhou B. Functions of thymic stromal lymphopoietin in immunity and disease [J]. Immunol Res，2012，52（3）：211-223.
[16] Alten R，Mischkewitz M，Stefanski AL，et al. Janus kinase inhibitors：State of the art in clinical use and future perspectives [J]. Z Rheumatol，2020，79（3）：241-254.
[17] Levy LL，Urban J，King BA. Treatment of Recalcitrant Atopic Dermatitis with the Oral Janu Kinase Inhibitor Tofacitinib Citrate [J]. J Am Acad Dermatol，2015，73（3）：395-399.
[18] Guttman-Yassky E，Tha?觭i D，Pangan AL，et al. Upadacitinib in adults with moderate to severe atopic dermatitis：16-week results from a randomized，placebo-controlled trial [J]. J Allergy Clin Immunol，2020，145（3）：877-884.
[19] Silverberg JI，Simpson EL，Thyssen JP，et al. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis：A Randomized Clinical Trial [J]. JAMA Dermatol，2020.
[20] Bissonnette R，Maari C，Forman S，et al. The oral Janus kinase/spleen tyrosine kinase inhibito ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis：results from a randomized double-blind placebo-controlled study [J]. Br J Dermatol，2019，181（4）：733-742.
[21] Cosgrove SB，Cleaver DM，King VL，et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease：safety，efficacy and quality of life [J]. Vet Dermatol，2015，26（3）：171-179.
[22] Olivry T，DeBoer DJ，Favrot C，et al. Treatment of canine atopic dermatitis：2015 updated guidelines from the International Committee on Allergic Diseases of Animals （ICADA） [J]. BMC Vet Res，2015，11：210.
[23] Haugh IM，Watson IT，Alan Menter M. Successful treatment of atopic dermatitis with the JAK1 inhibitor oclacitinib [J]. Proc（Bayl Univ Med Cent），2018，31（5）：524-525.
[24] Bissonnette R，Papp KA，Poulin Y，et al. Topical tofacitinib for atopic dermatitis：a phase Ⅱa randomized trial [J]. Br J Dermatol，2016，175（5）：902-911.
[25] Jin W，Huang W，Chen L，et al. Topical Application of JAK1/JAK2 Inhibitor Momelotinib Exhibits Significant Anti-Inflammatory Responses in DNCB-Induced Atopic Dermatitis Model Mice [J]. Int J Mol Sci，2018，19（12）：3973.
[26] Kim BS，Howell MD，Sun K，et al. Treatment of atopic dermatitis with ruxolitinib cream （JAK1/JAK2 inhibitor） or triamcinolone cream [J]. J Allergy Clin Immunol，2020， 145（2）：572-582.
[27] Nakagawa H，Nemoto O，Igarashi A，et al. Long-term safety and efficacy of delgocitinib ointment，a topical Janus kinase inhibitor，in adult patients with atopic dermatitis [J]. J Dermatol，2020，47（2）：114-120.
[28] Tanaka Y，Ishii T，Cai Z，et al. Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis：A 52-week，randomized，single-blind，extension study [J]. Mod Rheumatol，2018，28（1）：20-29.
[29] Winthrop KL，Park SH，Gul A，et al. Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis [J]. Ann Rheum Dis，2016， 75（6）：1133-1138.
[30] Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease [J]. Nat Rev Rheumatol，2017，13（4）：234-243.
2021, Vol. 18 
京公网安备 11010502046598号